169 related articles for article (PubMed ID: 32684368)
1. Occurrence of exocrine pancreatic insufficiency in patients with advanced neuroendocrine tumors treated with somatostatin analogs.
Rinzivillo M; De Felice I; Magi L; Annibale B; Panzuto F
Pancreatology; 2020 Jul; 20(5):875-879. PubMed ID: 32684368
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study.
Lamarca A; McCallum L; Nuttall C; Barriuso J; Backen A; Frizziero M; Leon R; Mansoor W; McNamara MG; Hubner RA; Valle JW
Expert Rev Gastroenterol Hepatol; 2018 Jul; 12(7):723-731. PubMed ID: 29923433
[TBL] [Abstract][Full Text] [Related]
3. Chronic Use of Long-Acting Somatostatin Analogues (SSAs) and Exocrine Pancreatic Insufficiency (EPI) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Under-recognized Adverse Effect.
Saif MW; Romano A; Smith MH; Patel R; Relias V
Cancer Med J; 2020; 3(2):75-84. PubMed ID: 32405630
[TBL] [Abstract][Full Text] [Related]
4. Exocrine pancreatic insufficiency following esophagectomy.
Huddy JR; Macharg FM; Lawn AM; Preston SR
Dis Esophagus; 2013 Aug; 26(6):594-7. PubMed ID: 23199208
[TBL] [Abstract][Full Text] [Related]
5. Exocrine pancreatic insufficiency in long-term follow-up after curative gastric resection with D2 lymphadenectomy: A cross-sectional study.
Surmelioglu A; Ozkardesler E; Tilki M; Yekrek M
Pancreatology; 2021 Aug; 21(5):975-982. PubMed ID: 33839030
[TBL] [Abstract][Full Text] [Related]
6. Screening for malnutrition in patients with gastro-entero-pancreatic neuroendocrine tumours: a cross-sectional study.
Qureshi SA; Burch N; Druce M; Hattersley JG; Khan S; Gopalakrishnan K; Darby C; Wong JL; Davies L; Fletcher S; Shatwell W; Sothi S; Randeva HS; Dimitriadis GK; Weickert MO
BMJ Open; 2016 May; 6(5):e010765. PubMed ID: 27147385
[TBL] [Abstract][Full Text] [Related]
7. Faecal elastase 1: not helpful in diagnosing chronic pancreatitis associated with mild to moderate exocrine pancreatic insufficiency.
Lankisch PG; Schmidt I; König H; Lehnick D; Knollmann R; Löhr M; Liebe S
Gut; 1998 Apr; 42(4):551-4. PubMed ID: 9616319
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Performance of Measurement of Fecal Elastase-1 in Detection of Exocrine Pancreatic Insufficiency: Systematic Review and Meta-analysis.
Vanga RR; Tansel A; Sidiq S; El-Serag HB; Othman MO
Clin Gastroenterol Hepatol; 2018 Aug; 16(8):1220-1228.e4. PubMed ID: 29374614
[TBL] [Abstract][Full Text] [Related]
9. Exocrine pancreatic insufficiency is common in people living with HIV on effective antiretroviral therapy.
Yilmaz A; Hagberg L
Infect Dis (Lond); 2018 Mar; 50(3):193-199. PubMed ID: 28838283
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Radiological Chronic Pancreatitis and Exocrine Pancreatic Insufficiency in Patients with Decompensated Liver Disease: Is Fecal Elastase Useful in This Setting?
Llibre-Nieto G; Lira A; Vergara M; Casas M; Solé C; Ferrusquía-Acosta J; Puig-Diví V; Grau-López L; Barradas JM; Solà M; Miquel M; Sánchez-Delgado J
Nutrients; 2023 Jan; 15(2):. PubMed ID: 36678246
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Exocrine Pancreatic Function Following Bariatric/Metabolic Surgery: a Prospective Cohort Study.
Çiçek Okuyan G; Akkuş D
Obes Surg; 2023 Jan; 33(1):25-31. PubMed ID: 36437437
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%?
Merola E; Alonso Gordoa T; Zhang P; Al-Toubah T; Pellè E; Kolasińska-Ćwikła A; Zandee W; Laskaratos F; de Mestier L; Lamarca A; Hernando J; Cwikla J; Strosberg J; de Herder W; Caplin M; Cives M; van Leeuwaarde R
Oncologist; 2021 Apr; 26(4):294-301. PubMed ID: 33301235
[TBL] [Abstract][Full Text] [Related]
13. Exocrine pancreatic function in patients with end-stage renal disease.
Griesche-Philippi J; Otto J; Schwörer H; Maisonneuve P; Lankisch PG
Clin Nephrol; 2010 Dec; 74(6):457-64. PubMed ID: 21084049
[TBL] [Abstract][Full Text] [Related]
14. Exocrine pancreatic insufficiency and somatostatin analogs in patients with neuroendocrine neoplasia.
Panzuto F; Magi L; Rinzivillo M
Expert Opin Drug Saf; 2021 Apr; 20(4):383-386. PubMed ID: 33530760
[No Abstract] [Full Text] [Related]
15. In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy.
Syguła A; Ledwon A; Hasse-Lazar K; Jurecka-Lubieniecka B; Michalik B; Paliczka-Cieślik E; Zeman M; Chmielik E; Sczasny J; Jarzab B; Handkiewicz-Junak D
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3841-3851. PubMed ID: 35503379
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
17. Low prevalence of exocrine pancreatic insufficiency in patients with diabetes mellitus.
Vujasinovic M; Zaletel J; Tepes B; Popic B; Makuc J; Epsek Lenart M; Predikaka M; Rudolf S
Pancreatology; 2013; 13(4):343-6. PubMed ID: 23890131
[TBL] [Abstract][Full Text] [Related]
18. Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.
Ćwikła JB; Bodei L; Kolasinska-Ćwikła A; Sankowski A; Modlin IM; Kidd M
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1437-45. PubMed ID: 26348352
[TBL] [Abstract][Full Text] [Related]
19. Exocrine Pancreatic Insufficiency after Roux-en-Y gastric bypass.
Borbély Y; Plebani A; Kröll D; Ghisla S; Nett PC
Surg Obes Relat Dis; 2016 May; 12(4):790-794. PubMed ID: 26965152
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects.
Mazziotti G; Mosca A; Frara S; Vitale G; Giustina A
Expert Opin Pharmacother; 2017 Nov; 18(16):1679-1689. PubMed ID: 29067877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
